Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer
Disease area: Interstitial lung diseases, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
G. Massard (Strasbourg, France). Contemporary surgical issues in NSCLC treatment. Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer

Member's Comments

No comment yet.

Related content which might interest you: Interstital lung diseases: update 2005 Source: Annual Congress 2005 - Clinical year in review Year: 2005 COVID-19: Current Challenges in ILD Source: ERS webinar 2020: COVID-19: Current Challenges in ILD Year: 2020 Bosentan in idiopathic pulmonary fibrosis (IPF): quality of life (QOL) results of the BUILD 1 study Source: Annual Congress 2006 - Quality of life in various respiratory diseases Year: 2006 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer Source: Eur Respir J 2013; 41: 262-269 Year: 2013 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Interstitial fibrosis with a nodule Source: Annual Congress 2007 - Thoracic Oncology Grand Round: an interactive session Year: 2007 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Source: Eur Respir Rev 2013; 22: 148-152 Year: 2013 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 T-cell pathways in lung tissue of patients with advanced COPD and IPF requiring lung transplantation Source: International Congress 2016 – Mechanisms of disease Year: 2016 Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 ERS guidelines on treatment of sarcoidosis Source: ERS webinar 2021: ERS guidelines on treatment of sarcoidosis Year: 2021 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016